KZA 0.00% 8.0¢ kazia therapeutics limited

Unravelling glioblastoma’s secrets and harnessing two decades of progress, page-5

  1. 114 Posts.
    lightbulb Created with Sketch. 125
    GBM AGILE also assesses paxalisib in recurrent GBM.
    There is no prior data on paxalisib in this sub-population.

    I also take it as a good sign that the results for paxalisib have not been published.
    Paxalisib was arguably easier to administer as an oral than an iv drug like VAL-083 - meaning that patient recruitment should have been faster.
    But VAL-083 was also assessed in methylated patients.

    A big question for me the split between newly-diagnosed vs recurrent cases in the paxalisib arm.

    John Friend confirmed in the latest IR video that GBM AGILE results for paxalisib are still on track for publication in 2023.
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.